NASDAQ:ALLK

Allakos - ALLK Stock Forecast, Price & News

$3.60

-0.23 (-6.01%)

(As of 08/11/2022 03:59 PM ET)

Add

Compare

Today's Range: $3.58
▼
$4.03
50-Day Range: $2.60
▼
$4.34
52-Week Range: $2.54
▼
$11.73

Volume: 56,988 shs
Average Volume: 765,832 shs
Market Capitalization: $197.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $66.80

Allakos MarketRank™ Forecast

Analyst Rating: Hold
2.10 Rating Score
Upside/Downside: 1,745.3% Upside
$66.80 Price Target
Short Interest: Healthy
7.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: 0.08
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.88) to ($3.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

134th out of 1,112 stocks

Pharmaceutical Preparations Industry

54th out of 544 stocks

3.1

Analyst's Opinion

Consensus Rating
Allakos has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 2 buy ratings, 7 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $66.80, Allakos has a forecasted upside of 1,745.3% from its current price of $3.62.
Amount of Analyst Coverage
Allakos has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
7.14% of the float of Allakos has been sold short.
Short Interest Ratio / Days to Cover
Allakos has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Allakos has recently decreased by 10.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Allakos does not currently pay a dividend.
Dividend Growth
Allakos does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Allakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Allakos is -0.86.

2.3

News and Social Media Coverage

News Sentiment
Allakos has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Allakos this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
MarketBeat Follows
7 people have added Allakos to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allakos insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.07% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Allakos are expected to grow in the coming year, from ($5.88) to ($3.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allakos is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allakos is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allakos has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Allakos (NASDAQ:ALLK) Stock

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Allakos in a research report on Monday, May 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $66.80.

Allakos Stock Down 3.9 %

Shares of NASDAQ:ALLK traded down $0.15 during trading on Thursday, reaching $3.68. The stock had a trading volume of 46,392 shares, compared to its average volume of 765,832. Allakos has a 52 week low of $2.54 and a 52 week high of $11.73. The firm has a market capitalization of $201.81 million, a price-to-earnings ratio of -0.52 and a beta of 0.86. The stock has a fifty day simple moving average of $3.37 and a two-hundred day simple moving average of $4.48.

Allakos (NASDAQ:ALLK - Get Rating) last announced its earnings results on Thursday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.04). On average, analysts forecast that Allakos will post -5.88 EPS for the current year.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

August 11, 2022 | globenewswire.com

Eczema Clinical Trial Pipeline Insights | DelveInsight - GlobeNewswire

August 11, 2022 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives Average Recommendation of "Hold" from Analysts

August 5, 2022 | finance.yahoo.com

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results - Yahoo Finance

August 4, 2022 | seekingalpha.com

Allakos GAAP EPS of -$0.90 misses by $0.11 (NASDAQ:ALLK) - Seeking Alpha

August 4, 2022 | globenewswire.com

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results - GlobeNewswire

August 4, 2022 | finance.yahoo.com

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

July 26, 2022 | finance.yahoo.com

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors - Yahoo Finance

July 25, 2022 | globenewswire.com

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors - GlobeNewswire

July 25, 2022 | finance.yahoo.com

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

July 18, 2022 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Sees Significant Drop in Short Interest

July 8, 2022 | finance.yahoo.com

Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky

June 17, 2022 | benzinga.com

Dow Jones Turns Lower; Revlon Shares Jump - Benzinga - Benzinga

June 16, 2022 | benzinga.com

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties - Benzinga

June 13, 2022 | benzinga.com

INVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Mana - Benzinga

June 10, 2022 | benzinga.com

INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Ma - Benzinga

June 8, 2022 | finance.yahoo.com

Aqualung Therapeutics Appoints Two New Board Directors; Will Attend June 22 Bio Meeting in San Diego - Yahoo Finance

May 27, 2022 | bizjournals.com

After a record-breaking decade, biotech is discovering what hard times feel like - San Francisco Business Times - The Business Journals

May 24, 2022 | benzinga.com

Goldman Sachs Maintains Neutral on Allakos, Lowers Price Target to $4 - Benzinga - Benzinga

May 18, 2022 | streetinsider.com

Allakos Inc. (ALLK) PT Lowered to $10 at Cantor Fitzgerald, But BUY Rating Maintained, "Still Believe that the Market Opportunity for lirentelimab is Underappreciated" - StreetInsider.com

May 13, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Allakos

May 12, 2022 | benzinga.com

What 4 Analyst Ratings Have To Say About Allakos - Benzinga - Benzinga

May 12, 2022 | benzinga.com

SVB Leerink Maintains Market Perform on Allakos, Lowers Price Target to $12 - Benzinga - Benzinga

May 10, 2022 | benzinga.com

Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $6 - Benzinga - Benzinga

May 9, 2022 | ca.investing.com

Pre-Open Stock Movers 05/09: Energizer, Tyson Gain on Earnings; Rivian Sinks on Lock-Up Expiration (more...) By Investing.com - Investing.com Canada

May 9, 2022 | investing.com

Pre-Open Stock Movers 05/09: Energizer, Tyson Gain on Earnings; Rivian Sinks on Lock-Up Expiration (more...) By Investing.com - Investing.com

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Company Calendar

Last Earnings: 8/04/2022
Today: 8/11/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALLK
CUSIP: N/A
CIK: 1564824
Web: www.allakos.com
Phone: (650) 597-5002
Fax: N/A
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $66.80
High Stock Price Forecast: $155.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +1,755.6%
Consensus Rating: Hold
Rating Score (0-4): 2.10
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-269,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -111.03%
Return on Assets: -89.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.08
Quick Ratio: 6.08

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.06 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 54,840,000
Free Float: 36,608,000
Market Cap: $197.42 million
Optionable: Not Optionable
Beta: 0.86

Key Executives

Dr. Robert Alexander Ph.D. (Age 52)
CEO & Director
Comp: $1.39M
Dr. Adam L. Tomasi Ph.D. (Age 52)
Pres & COO
Comp: $1.06M
Mr. Baird Radford III
Chief Financial Officer
Dr. Ruby Casareno Ph.D.
Sr. VP of Technical Operations
Meg Fitzgerald
Sr. VP, Gen. Counsel, Sec. and Chief Compliance Officer
Dr. Sally D. Bolmer
Sr. VP of Regulatory Affairs & Drug Devel.
Dr. Henrik Sandvad Rasmussen (Age 63)
Strategic Advisor
Dr. Craig Paterson M.D.
Chief Medical Officer
Brad Youngblood
Head of Research
Mr. Alan Chang
Director of Medical Affairs & Data Analytics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings or view top-rated stocks.
What is Allakos' stock price forecast for 2022?: 10 brokers have issued 1 year target prices for Allakos' shares. Their ALLK share price forecasts range from $13.00 to $155.00. On average, they predict the company's stock price to reach $66.80 in the next year. This suggests a possible upside of 1,690.9% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.
How have ALLK shares performed in 2022?: Allakos' stock was trading at $9.79 at the start of the year. Since then, ALLK stock has decreased by 61.9% and is now trading at $3.73.
View the best growth stocks for 2022 here.
When is Allakos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ALLK earnings forecast.
How were Allakos' earnings last quarter?: Allakos Inc. (NASDAQ:ALLK) announced its quarterly earnings data on Thursday, August, 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by $0.05.
What other stocks do shareholders of Allakos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?: (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.
What is Allakos' stock symbol?: Allakos trades on the NASDAQ under the ticker symbol "ALLK."
Who are Allakos' major shareholders?: Allakos' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.12%), Walleye Capital LLC (0.44%), Connor Clark & Lunn Investment Management Ltd. (0.32%), UBS Group AG (0.31%), Bank of Montreal Can (0.24%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends.
How do I buy shares of Allakos?: Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Allakos' stock price today?: One share of ALLK stock can currently be purchased for approximately $3.73.
How much money does Allakos make?: Allakos (NASDAQ:ALLK) has a market capitalization of $204.55 million. The company earns $-269,860,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.
How many employees does Allakos have?: The company employs 192 workers across the globe.
How can I contact Allakos?: Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 8/11/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Allakos - ALLK Stock Forecast, Price & News

Allakos MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Allakos (NASDAQ:ALLK) Stock

Analysts Set New Price Targets

Allakos Stock Down 3.9 %

ALLK Stock News Headlines

ALLK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

What is Allakos' stock price forecast for 2022?

How have ALLK shares performed in 2022?

When is Allakos' next earnings date?

How were Allakos' earnings last quarter?

What other stocks do shareholders of Allakos own?

When did Allakos IPO?

What is Allakos' stock symbol?

Who are Allakos' major shareholders?

How do I buy shares of Allakos?

What is Allakos' stock price today?

How much money does Allakos make?

How many employees does Allakos have?

How can I contact Allakos?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™